Skip to main content
. 2023 Aug 30;35(4):399–407. doi: 10.21147/j.issn.1000-9604.2023.04.06

Table 3. All AEs resulting from TACE treatment in patients with HCC (N=36).

AEs n (%)
Any grade Grade 3
AE, adverse event; TACE, transcatheter arterial chemoembolization; HCC, hepatocellular carcinoma. *, included elevation of transaminase, bilirubin and g-glutamyltranspeptidase.
Abdominal pain 27 (75.0) 4 (11.1)
Liver function injury* 9 (25.0) 0 (0)
Nausea 4 (11.1) 0 (0)
Abdominal distension 3 (8.3) 0 (0)
Vomiting 1 (2.8) 0 (0)
Appetite loss 1 (2.8) 0 (0)